Publicaciones en las que colabora con José Alejandro Pérez Fidalgo (21)

2022

  1. Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients

    Cancers, Vol. 14, Núm. 5

2020

  1. Aurora kinases in ovarian cancer

    ESMO Open, Vol. 5, Núm. 5

2019

  1. A logarithmic rapid desensitization protocol: initial experience in carboplatin hypersensitivity reactions

    Journal of Cancer Metastasis and Treatment, Vol. 5

2018

  1. In the literature: June 2018

    ESMO Open, Vol. 3, Núm. 4

  2. Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii339

  3. Soft tissue sarcomas (STS) in elder patients: No impact of age on overall survival (OS) in an unselected cohort

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii593

2017

  1. A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors

    Cancer Discovery, Vol. 7, Núm. 1, pp. 102-113

2016

  1. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 160, Núm. 1, pp. 69-77

  2. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

    Oncotarget, Vol. 7, Núm. 16, pp. 22543-22555

2015

  1. Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer

    Oncotarget, Vol. 6, Núm. 29, pp. 26935-26945

  2. EGF-Induced acetylation of heterogeneous nuclear ribonucleoproteins is dependent on KRAS mutational status in colorectal cancer cells

    PLoS ONE, Vol. 10, Núm. 6

  3. Primary paraesophageal ewing’s sarcoma: An uncommon case report and literature review

    OncoTargets and Therapy, Vol. 8, pp. 1053-1059

2013

  1. Current questions for the treatment of advanced gastric cancer

    Cancer Treatment Reviews, Vol. 39, Núm. 1, pp. 60-67

2012

  1. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines

    Annals of Oncology, Vol. 23, Núm. SUPPL. 7

  2. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines

    European Journal of Oncology Nursing, Vol. 16, Núm. 5, pp. 528-534

  3. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 18, Núm. 17, pp. 4764-4774

2011

  1. Tratamiento neoadyuvante del cáncer de recto

    Revisiones en Cancer, Vol. 25, Núm. 2, pp. 62-72

2009

  1. Aurora kinase inhibitors: A new class of drugs targeting the regulatory mitotic system

    Clinical and Translational Oncology, Vol. 11, Núm. 12, pp. 787-798

2007

  1. La encefalopatía hiperamonémica, una posible complicación por derivación urinaria tras cistectomía radical. Revisión de la literatura a proposito de un caso

    Actas Urologicas Espanolas, Vol. 31, Núm. 4, pp. 394-399

  2. La quimioterapia en el tratamiento del cáncer de esófago

    Revisiones en Cancer, Vol. 21, Núm. 2, pp. 102-112